| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.068 | 0.09 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.09 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.092 | 0.09 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.09 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.09 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.084 | 0.09 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.09 |